EUCTR2013-000123-13-BE进行中（未招募）1 期
A single arm multi-center study investigating the at home administration of trastuzumab subcutaneous vial for the treatment of patients with HER2-positive early breast cancer - Umbrella_BELIS
V ROCHE SA0 个研究点目标入组 100 人开始时间: 2013年7月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Female and male patients aged = 18 years
- •2.Signed informed consent prior to any study specific procedure
- •3.Able and willing to comply with protocol
- •4.Eastern Cooperative Oncology Group (ECOG) performance status 0–1
- •5.Hormonal therapy will be allowed as per institutional guidelines
- •6.Left ventricular ejection fraction (LVEF) of = 50% measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC, or, for those who were receiving trastuzumab when beginning the study, documented results within an acceptable limit from a cardiac assessment within 3 months prior to enrolment
- •7.HER2-positive disease immunohistochemistry (IHC)3+ or in situ hybridization (ISH) positive, in line with local reimbursement criteria and determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay
- •8.Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast
- •9.No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or adjuvant)
- •10.Use of concurrent curative radiotherapy will be permitted
- •11.Patients have completed the first 6 cycles of trastuzumab IV as part of the (neo)adjuvant treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.History of other malignancy which could affect compliance with the protocol or interpretation of results. Patients with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and patients with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible
- •2.Patients with severe dyspnea at rest or requiring supplementary oxygen therapy
- •3.Patients with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
- •4.Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension
- •5.Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)
- •6.Pregnant or lactating women. Positive serum pregnancy test in women of childbearing potential, premenopausal or less than 12 months of amenorrhea post-menopause, within 7 days prior to the first dose of study drug
- •7.Women of childbearing potential, premenopausal or less than 12 months of amenorrhea post-menopause (unless surgically sterile), and male patients with partners of childbearing potential who are unable or unwilling to use adequate contraceptive measures during study treatment. In this study, menopause is defined as a minimum of 12 consecutive months of amenorrhea during which time no other biological or physiological cause had been identified as a potential cause of this state. Examples of adequate contraceptive measures are intrauterine device, barrier method (condoms, diaphragm) also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not acceptable
- •8.Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
- •9.Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin® including hyaluronidase, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g. difficult to control asthma
- •10.Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
- •11.Inadequate bone marrow function (as indicated by any of the following):
- •a)Absolute neutrophil count (ANC) < 1,500 / mm3 (< 1.5 × 109/L)
- •b)Platelets < 100,000 / mm3 (< 100 × 109/L)
- •Hemoglobin < 10 g/dL
- •12.Impaired hepatic function (as indicated by any of the following):
- •a)Serum total bilirubin > 1.5 × upper limit of normal (ULN)
- •b)Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) > 2.5 × ULN
- •c)Alkaline phosphatase (ALP) > 2.5 × ULN
- •13.Inadequate renal function, as indicated by serum creatinine > 1.5 × ULN
研究者
相似试验
招募中
3 期
A study to investigate the pharmacokinetics and safety of dupilumab in participants >=2 years to < 12 years of age with uncontrolled chronic spontaneous urticaria (CSU) or chronic inducible cold urticaria (CICU)JPRN-jRCT2031220733Tanaka Tomoyuki24
已完成
不适用
Prospective Multi-Center, Single Arm Study of the Shockwave Coronary Rx Lithoplasty® System in Coronary Arteriesarterial stenosisstenotic coronary arteries10011082NL-OMON43455Shockwave Medical Inc.15
尚未招募
Unknown
A multi-center, single-arm clinical study for the efficacy and safety of '10THERMA' on tissue coagulation and skin rejuvenatioFactors influencing health status and contact with health servicesKCT0008709Korean Society for Laser Medicine and Sugery31
招募中
Unknown
PASSAGE Clinical TrialJPRN-jRCT2032220496Kawahara Kazuo51
进行中（未招募）
1 期
OncoSur Analysis of the Treatment in Third Line of ABC with Eribuli-MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-001416-30-ESFundación Oncosur60